Fiyz̤ (Jun 2022)

Prevalence of prostate cancer in MRI-TRUS fusion biopsy patients with suspected lesion in Multi-Parametric MRI with PI-RADS 2 and 3 who have previously undergone prostate biopsy

  • Katebi K,
  • Khaleghi MR,
  • Bakhshandeh H,
  • Ghafoori M

Journal volume & issue
Vol. 26, no. 2
pp. 220 – 227

Abstract

Read online

Background: Prostate cancer is the most common cancer among men over seventy years. Prevalence of prostate cancer is reported diversely in PIRADS2,3 group in Multi-parametric MRI in previous studies and there is no similar examinations in Iran. The present study was investigated to prevalence of prostate cancer in these patients in Iranians for the first time, retrospectively. Materials and Methods: This cross-sectional study was performed in 2019 on 159 patients with suspected prostate cancer in Hazrat Rasoul Hospital. After obtaining informed consent, age and PSA levels, multi-parametric MRI results and MRI/TRUS Fusion Biopsy pathologic results was determined. Data analysis was performed using Statistical tests in SPSS 22 software. Results: The mean age of the patients was 61.96±8.49 years. The mean prostate volume of these patients was 59.57±31.09 with a range of (178-208). According to MRI results 61.6% had PI-RADS3, and 38.4% had PI-RADS2. There was no significant relationship between age, prostate volume, and PI-RADS (P>0.05). Prostate volume increased significantly with age. According to biopsy results, 23.3% had cancer and 76.7% had benign prostatic hyperplasia. The prevalence of cancer was 19.7% in PI-RADS2, and 25.5% in PI-RADS3. Conclusion: The prevalence of cancer in patients with PI-RADS2,3 lesions was 23.3%, which comprises a significant portion of patients. Biopsy in PI-RADS2,3 cases, considering the patient's condition, seems to lead to the diagnosis of a significant number of cancer cases.

Keywords